Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2011

Open Access 01-12-2011 | Research article

A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control

Authors: Barbara J Turner, Christopher S Hollenbeak, Mark Weiner, Simon SK Tang

Published in: BMC Cardiovascular Disorders | Issue 1/2011

Login to get access

Abstract

Background

Reasons for race and gender differences in controlling elevated low density lipoprotein (LDL) cholesterol may be related to variations in prescribed lipid-lowering therapy. We examined the effect of lipid-lowering drug treatment and potency on time until LDL control for black and white women and men with a baseline elevated LDL.

Methods

We studied 3,484 older hypertensive patients with dyslipidemia in 6 primary care practices over a 4-year timeframe. Potency of lipid-lowering drugs calculated for each treated day and summed to assess total potency for at least 6 and up to 24 months. Cox models of time to LDL control within two years and logistic regression models of control within 6 months by race-gender adjust for: demographics, clinical, health care delivery, primary/specialty care, LDL measurement, and drug potency.

Results

Time to LDL control decreased as lipid-lowering drug potency increased (P < 0.001). Black women (N = 1,440) received the highest potency therapy (P < 0.001) yet were less likely to achieve LDL control than white men (N = 717) (fully adjusted hazard ratio [HR] 0.66 [95% CI 0.56-0.78]). Black men (N = 666) and white women (N = 661) also had lower adjusted HRs of LDL control (0.82 [95% CI 0.69, 0.98] and 0.75 [95% CI 0.64-0.88], respectively) than white men. Logistic regression models of LDL control by 6 months and other sensitivity models affirmed these results.

Conclusions

Black women and, to a lesser extent, black men and white women were less likely to achieve LDL control than white men after accounting for lipid-lowering drug potency as well as diverse patient and provider factors. Future work should focus on the contributions of medication adherence and response to treatment to these clinically important differences.
Appendix
Available only for authorised users
Literature
1.
go back to reference Expert Panel on Detection, Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of The National Cholesterol Education Program [NCEP] Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults [Adult Treatment Panel III]. JAMA. 2001, 285 (19): 2486-97. 10.1001/jama.285.19.2486.CrossRef Expert Panel on Detection, Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of The National Cholesterol Education Program [NCEP] Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults [Adult Treatment Panel III]. JAMA. 2001, 285 (19): 2486-97. 10.1001/jama.285.19.2486.CrossRef
2.
go back to reference Pletcher MJ, Lazar L, Bibbins-Domingo K, et al: Comparing impact and cost effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009, 150: 243-54.CrossRefPubMed Pletcher MJ, Lazar L, Bibbins-Domingo K, et al: Comparing impact and cost effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009, 150: 243-54.CrossRefPubMed
3.
go back to reference Ford ES, Li C, Pearson WS, Zhao G, et al: Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol. 2008, [Epub] Ford ES, Li C, Pearson WS, Zhao G, et al: Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol. 2008, [Epub]
4.
go back to reference Sequist TD, Adams A, Zhang F, et al: Effect of quality improvement on racial disparities in diabetes care. Arch Intern Med. 2006, 166: 675-81. 10.1001/archinte.166.6.675.CrossRefPubMed Sequist TD, Adams A, Zhang F, et al: Effect of quality improvement on racial disparities in diabetes care. Arch Intern Med. 2006, 166: 675-81. 10.1001/archinte.166.6.675.CrossRefPubMed
5.
go back to reference Persell SD, Maviglia SM, Bates DW, et al: Ambulatory hypercholesterolemia management in patients with atherosclerosis. Gender and race differences in processes and outcomes. J Gen Intern Med. 2005, 20 (2): 123-30. 10.1111/j.1525-1497.2005.40155.x.CrossRefPubMedPubMedCentral Persell SD, Maviglia SM, Bates DW, et al: Ambulatory hypercholesterolemia management in patients with atherosclerosis. Gender and race differences in processes and outcomes. J Gen Intern Med. 2005, 20 (2): 123-30. 10.1111/j.1525-1497.2005.40155.x.CrossRefPubMedPubMedCentral
6.
go back to reference Gouni-Berthold I, Berthold HK, Mantzoros CS, et al: Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care. 2008, 31 (7): 1389-91. 10.2337/dc08-0194.CrossRefPubMedPubMedCentral Gouni-Berthold I, Berthold HK, Mantzoros CS, et al: Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care. 2008, 31 (7): 1389-91. 10.2337/dc08-0194.CrossRefPubMedPubMedCentral
7.
go back to reference O'Meara JG, Kardia SL, Armon JJ, et al: Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 2004, 164 (12): 1313-8. 10.1001/archinte.164.12.1313.CrossRefPubMed O'Meara JG, Kardia SL, Armon JJ, et al: Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 2004, 164 (12): 1313-8. 10.1001/archinte.164.12.1313.CrossRefPubMed
8.
go back to reference Ferrara A, Mangione CM, Kim C, et al: Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes [TRIAD] Study. Diabetes Care. 2008, 31 (1): 69-74. 10.2337/dc08-1082.CrossRefPubMed Ferrara A, Mangione CM, Kim C, et al: Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: Translating Research Into Action for Diabetes [TRIAD] Study. Diabetes Care. 2008, 31 (1): 69-74. 10.2337/dc08-1082.CrossRefPubMed
9.
go back to reference Bailey KR, Grossardt BR, Graves JW: Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates. Hypertension. 2008, 51: 841-7. 10.1161/HYPERTENSIONAHA.107.101659.CrossRefPubMedPubMedCentral Bailey KR, Grossardt BR, Graves JW: Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates. Hypertension. 2008, 51: 841-7. 10.1161/HYPERTENSIONAHA.107.101659.CrossRefPubMedPubMedCentral
10.
go back to reference Turner BJ, Hollenbeak CS, Weiner M, et al: Effect of unrelated comorbid conditions on hypertension management. Ann Intern Med. 2008, 148: 578-86.CrossRefPubMed Turner BJ, Hollenbeak CS, Weiner M, et al: Effect of unrelated comorbid conditions on hypertension management. Ann Intern Med. 2008, 148: 578-86.CrossRefPubMed
11.
go back to reference Lagu T, Weiner MG, Hollenbeak CS, Roberts CS, Schwartz JS, Turner BJ: The impact of concordant and discordant conditions on the quality of care for hyperlipidemia. J Gen Intern Med. 2008, 23 (8): 1208-13. 10.1007/s11606-008-0647-4.CrossRefPubMedPubMedCentral Lagu T, Weiner MG, Hollenbeak CS, Roberts CS, Schwartz JS, Turner BJ: The impact of concordant and discordant conditions on the quality of care for hyperlipidemia. J Gen Intern Med. 2008, 23 (8): 1208-13. 10.1007/s11606-008-0647-4.CrossRefPubMedPubMedCentral
12.
go back to reference Grundy SM, Cleeman JI, Merz CN, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004, 110 (2): 227-39. 10.1161/01.CIR.0000133317.49796.0E.CrossRefPubMed Grundy SM, Cleeman JI, Merz CN, et al: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004, 110 (2): 227-39. 10.1161/01.CIR.0000133317.49796.0E.CrossRefPubMed
13.
go back to reference Hou R, Goldberg AC: Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin N Am. 2009, 38: 79-97. 10.1016/j.ecl.2008.11.007.CrossRef Hou R, Goldberg AC: Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin N Am. 2009, 38: 79-97. 10.1016/j.ecl.2008.11.007.CrossRef
15.
go back to reference Sharma M, Ansari MT, Abou-Setta AM, et al: Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med. 2009, 151 (9): 622-30.CrossRefPubMed Sharma M, Ansari MT, Abou-Setta AM, et al: Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med. 2009, 151 (9): 622-30.CrossRefPubMed
16.
go back to reference Gross R, Weiner MG, et al: Racial disparities in hypertension control, but not treatment intensification. Am J Hypertens. 2010, 23 (1): 54-61. 10.1038/ajh.2009.201.CrossRefPubMed Gross R, Weiner MG, et al: Racial disparities in hypertension control, but not treatment intensification. Am J Hypertens. 2010, 23 (1): 54-61. 10.1038/ajh.2009.201.CrossRefPubMed
17.
go back to reference Willson MN, Neumiller JJ, Sclar DA, Robison LM, Skaer TL: Ethnicity/race, use of pharmacotherapy, scope of physician-ordered cholesterol screening, and provision of diet/nutrition or exercise counseling during US office-based visits by patients with hyperlipidemia. Am J Cardiovasc Drugs. 2010, 10 (2): 105-8. 10.2165/11532820-000000000-00000.CrossRefPubMed Willson MN, Neumiller JJ, Sclar DA, Robison LM, Skaer TL: Ethnicity/race, use of pharmacotherapy, scope of physician-ordered cholesterol screening, and provision of diet/nutrition or exercise counseling during US office-based visits by patients with hyperlipidemia. Am J Cardiovasc Drugs. 2010, 10 (2): 105-8. 10.2165/11532820-000000000-00000.CrossRefPubMed
18.
go back to reference Santos RD, Waters DD, Tarasenko L, et al: Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project [L-TAP] 2. Am Heart J. 2009, 158 (5): 860-6. 10.1016/j.ahj.2009.08.009.CrossRefPubMed Santos RD, Waters DD, Tarasenko L, et al: Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project [L-TAP] 2. Am Heart J. 2009, 158 (5): 860-6. 10.1016/j.ahj.2009.08.009.CrossRefPubMed
19.
go back to reference Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL: Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Womens Health [Larchmt]. 2008, 17 (4): 515-21. 10.1089/jwh.2007.0443.CrossRef Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL: Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Womens Health [Larchmt]. 2008, 17 (4): 515-21. 10.1089/jwh.2007.0443.CrossRef
20.
go back to reference Mark TL, Axelsen KJ, Mucha L, Sadkova Y: Racial differences in switching, augmentation, and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients. Am J Manag Care. 2007, 13 (Suppl 3): S72-9.PubMed Mark TL, Axelsen KJ, Mucha L, Sadkova Y: Racial differences in switching, augmentation, and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients. Am J Manag Care. 2007, 13 (Suppl 3): S72-9.PubMed
21.
go back to reference Mensah GA, Mokdad AH, Ford ES, et al: State of disparities in cardiovascular health in the United States. Circulation. 2005, 111 (10): 1233-41. 10.1161/01.CIR.0000158136.76824.04.CrossRefPubMed Mensah GA, Mokdad AH, Ford ES, et al: State of disparities in cardiovascular health in the United States. Circulation. 2005, 111 (10): 1233-41. 10.1161/01.CIR.0000158136.76824.04.CrossRefPubMed
22.
go back to reference O'Meara JG, Kardia SL, Armon JJ, et al: Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 2004, 164 (12): 1313-8. 10.1001/archinte.164.12.1313.CrossRefPubMed O'Meara JG, Kardia SL, Armon JJ, et al: Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 2004, 164 (12): 1313-8. 10.1001/archinte.164.12.1313.CrossRefPubMed
23.
go back to reference Ferdinand KC, Clark LT, Watson KE, et al: Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006, 97 (2): 229-35;. 10.1016/j.amjcard.2005.08.026.CrossRefPubMed Ferdinand KC, Clark LT, Watson KE, et al: Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006, 97 (2): 229-35;. 10.1016/j.amjcard.2005.08.026.CrossRefPubMed
24.
go back to reference Fong RL, Ward HJ: The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia. Am J Med. 1997, 102 (4): 387-91. 10.1016/S0002-9343(97)00091-0.CrossRefPubMed Fong RL, Ward HJ: The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia. Am J Med. 1997, 102 (4): 387-91. 10.1016/S0002-9343(97)00091-0.CrossRefPubMed
25.
go back to reference Mostaghel E, Waters D: Women do benefit from lipid lowering: latest clinical trial data. Cardiol Rev. 2003, 11 (1): 4-12. 10.1097/00045415-200301000-00003.CrossRefPubMed Mostaghel E, Waters D: Women do benefit from lipid lowering: latest clinical trial data. Cardiol Rev. 2003, 11 (1): 4-12. 10.1097/00045415-200301000-00003.CrossRefPubMed
26.
go back to reference Chan DC, Shrank WH, Cutler D, et al: Patient, physician, and payment predictors of statin adherence. Med Care. 2010, 48 (3): 196-202. 10.1097/MLR.0b013e3181c132ad.CrossRefPubMed Chan DC, Shrank WH, Cutler D, et al: Patient, physician, and payment predictors of statin adherence. Med Care. 2010, 48 (3): 196-202. 10.1097/MLR.0b013e3181c132ad.CrossRefPubMed
27.
go back to reference Litaker D, Koroukian SM: Racial differences in lipid-lowering agent use in Medicaid patients with cardiovascular disease. Med Care. 2004, 42 (10): 1009-18. 10.1097/00005650-200410000-00010.CrossRefPubMed Litaker D, Koroukian SM: Racial differences in lipid-lowering agent use in Medicaid patients with cardiovascular disease. Med Care. 2004, 42 (10): 1009-18. 10.1097/00005650-200410000-00010.CrossRefPubMed
28.
go back to reference Brookhart MA, Patrick AR, Schneeweiss S, et al: Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007, 167 (8): 847-52. 10.1001/archinte.167.8.847.CrossRefPubMed Brookhart MA, Patrick AR, Schneeweiss S, et al: Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007, 167 (8): 847-52. 10.1001/archinte.167.8.847.CrossRefPubMed
29.
go back to reference Mann DM, Allegrante JP, Natarajan S, et al: Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 2007, 21 (4): 311-6. 10.1007/s10557-007-6040-4.CrossRefPubMed Mann DM, Allegrante JP, Natarajan S, et al: Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther. 2007, 21 (4): 311-6. 10.1007/s10557-007-6040-4.CrossRefPubMed
30.
go back to reference McGinnis B, Olson KL, Magid D, et al: Factors related to adherence to statin therapy. Ann Pharmacother. 2007, 41 (11): 1805-11. 10.1345/aph.1K209.CrossRefPubMed McGinnis B, Olson KL, Magid D, et al: Factors related to adherence to statin therapy. Ann Pharmacother. 2007, 41 (11): 1805-11. 10.1345/aph.1K209.CrossRefPubMed
31.
go back to reference Yilmaz MB, Pinar M, Naharci I, et al: Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther. 2005, 19 (6): 437-40. 10.1007/s10557-005-5202-5.CrossRefPubMed Yilmaz MB, Pinar M, Naharci I, et al: Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther. 2005, 19 (6): 437-40. 10.1007/s10557-005-5202-5.CrossRefPubMed
32.
go back to reference Casebeer L, Huber C, Bennett N, et al: Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract. 2009, 10: 48-10.1186/1471-2296-10-48.CrossRefPubMedPubMedCentral Casebeer L, Huber C, Bennett N, et al: Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract. 2009, 10: 48-10.1186/1471-2296-10-48.CrossRefPubMedPubMedCentral
33.
go back to reference Gibson TB, Mark TL, Axelsen K, et al: Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006, 12: SP11-9.PubMed Gibson TB, Mark TL, Axelsen K, et al: Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006, 12: SP11-9.PubMed
34.
go back to reference Sedjo RL, Cox ER: Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manag Care. 2008, 14 (12): 813-8.PubMed Sedjo RL, Cox ER: Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manag Care. 2008, 14 (12): 813-8.PubMed
35.
go back to reference Chernew ME, Shah MR, Wegh A, et al: Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff [Millwood]. 2008, 27 (1): 103-12. 10.1377/hlthaff.27.1.103.CrossRef Chernew ME, Shah MR, Wegh A, et al: Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff [Millwood]. 2008, 27 (1): 103-12. 10.1377/hlthaff.27.1.103.CrossRef
36.
go back to reference Hartz I, Sakshaug S, Furu K, et al: Norwegian counties with high, average and low statin consumption - an individual-level prescription database study. BMC Clin Pharmacol. 2007, 7: 14-CrossRefPubMedPubMedCentral Hartz I, Sakshaug S, Furu K, et al: Norwegian counties with high, average and low statin consumption - an individual-level prescription database study. BMC Clin Pharmacol. 2007, 7: 14-CrossRefPubMedPubMedCentral
37.
go back to reference Hayward RA, Krumholz H, Zulman DM, Timble JW, Vijan S: Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010, 152: 69-77.CrossRefPubMed Hayward RA, Krumholz H, Zulman DM, Timble JW, Vijan S: Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010, 152: 69-77.CrossRefPubMed
38.
go back to reference Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB: Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004, 164 (21): 2343-8. 10.1001/archinte.164.21.2343.CrossRefPubMed Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB: Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004, 164 (21): 2343-8. 10.1001/archinte.164.21.2343.CrossRefPubMed
39.
go back to reference Chapman RH, Benner JS, Girase P, et al: Generic and therapeutic statin switches and disruptions in therapy. Curr Med Res Opin. 2009, 25 (5): 1247-60. 10.1185/03007990902876271.CrossRefPubMed Chapman RH, Benner JS, Girase P, et al: Generic and therapeutic statin switches and disruptions in therapy. Curr Med Res Opin. 2009, 25 (5): 1247-60. 10.1185/03007990902876271.CrossRefPubMed
40.
go back to reference Becker DM, Yanek LR, Johnson WR, et al: Impact of a community-based multiple risk factor intervention on cardiovascular risk in black families with a history of premature coronary disease. Circulation. 2005, 111 (10): 1298-304. 10.1161/01.CIR.0000157734.97351.B2.CrossRefPubMed Becker DM, Yanek LR, Johnson WR, et al: Impact of a community-based multiple risk factor intervention on cardiovascular risk in black families with a history of premature coronary disease. Circulation. 2005, 111 (10): 1298-304. 10.1161/01.CIR.0000157734.97351.B2.CrossRefPubMed
Metadata
Title
A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control
Authors
Barbara J Turner
Christopher S Hollenbeak
Mark Weiner
Simon SK Tang
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2011
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/1471-2261-11-58

Other articles of this Issue 1/2011

BMC Cardiovascular Disorders 1/2011 Go to the issue